Global Cephalosporin Drugs Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-04-23
- Report ID: 104766
- Pages: 114
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Cephalosporin Drugs market in this environment.
In terms of revenue, this research report indicated that the global Cephalosporin Drugs market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Cephalosporin Drugs industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Allergan aims at producing XX K Units Cephalosporin Drugs in 2020, with XX % production to take place in global market, Astellas accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Cephalosporin Drugs Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Cephalosporin Drugs Market
Allergan
Astellas
Bristol-Myers Squibb
GSK
Merck
Pfizer
Sandoz
Orchid Company
Lupin
TEVA
HPGC
Aurobindo
LKPC
Alkem
CSPC
Taj Pharma
DHANUKA LABORATORIES
CordenPharma
SRS Pharmaceuticals
Ankur Drugs and Pharma
...
Major Type of Cephalosporin Drugs Covered in Prudent Markets report:
1st Generation
2nd Generation
3rd Generation
4th Generation
Application Segments Covered in Prudent Markets Market
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Cephalosporin Drugs Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 1st Generation -Product Introduction and Major Manufacturers
1.1.2 2nd Generation -Product Introduction and Major Manufacturers
1.1.3 3rd Generation -Product Introduction and Major Manufacturers
1.1.4 4th Generation -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Cephalosporin Drugs Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Cephalosporin Drugs Market
3.1.1 Top Companies leading Cephalosporin Drugs Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Cephalosporin Drugs Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Cephalosporin Drugs Market
3.2.1 Top Companies leading Cephalosporin Drugs Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Cephalosporin Drugs Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Cephalosporin Drugs Market
3.3.1 Top Companies leading Cephalosporin Drugs Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Cephalosporin Drugs Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Cephalosporin Drugs Market
3.4.1 Top Companies leading Cephalosporin Drugs Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Cephalosporin Drugs Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Cephalosporin Drugs Market
3.5.1 Top Companies leading Cephalosporin Drugs Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Cephalosporin Drugs Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Cephalosporin Drugs Market
3.6.1 Top Companies leading Cephalosporin Drugs Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Cephalosporin Drugs Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Cephalosporin Drugs Market
3.7.1 Top Companies leading Cephalosporin Drugs Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Cephalosporin Drugs Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Cephalosporin Drugs Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Cephalosporin Drugs Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Cephalosporin Drugs Sales and Growth Rate (2021-2027)
5.2 Global Cephalosporin Drugs Sales Value and Growth Rate (2021-2027)
6 Cephalosporin Drugs Competitive Analysis
6.1 Allergan
6.1.1 Allergan Company Profiles
6.1.2 Allergan Product Introduction
6.1.3 Allergan Cephalosporin Drugs Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 Astellas
6.2.1 Astellas Company Profiles
6.2.2 Astellas Product Introduction
6.2.3 Astellas Cephalosporin Drugs Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Bristol-Myers Squibb
6.3.1 Bristol-Myers Squibb Company Profiles
6.3.2 Bristol-Myers Squibb Product Introduction
6.3.3 Bristol-Myers Squibb Cephalosporin Drugs Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 GSK
6.4.1 GSK Company Profiles
6.4.2 GSK Product Introduction
6.4.3 GSK Cephalosporin Drugs Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Merck
6.5.1 Merck Company Profiles
6.5.2 Merck Product Introduction
6.5.3 Merck Cephalosporin Drugs Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Pfizer
6.6.1 Pfizer Company Profiles
6.6.2 Pfizer Product Introduction
6.6.3 Pfizer Cephalosporin Drugs Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Sandoz
6.7.1 Sandoz Company Profiles
6.7.2 Sandoz Product Introduction
6.7.3 Sandoz Cephalosporin Drugs Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Orchid Company
6.8.1 Orchid Company Company Profiles
6.8.2 Orchid Company Product Introduction
6.8.3 Orchid Company Cephalosporin Drugs Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Lupin
6.9.1 Lupin Company Profiles
6.9.2 Lupin Product Introduction
6.9.3 Lupin Cephalosporin Drugs Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 TEVA
6.10.1 TEVA Company Profiles
6.10.2 TEVA Product Introduction
6.10.3 TEVA Cephalosporin Drugs Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 HPGC
6.12 Aurobindo
6.13 LKPC
6.14 Alkem
6.15 CSPC
6.16 Taj Pharma
6.17 DHANUKA LABORATORIES
6.18 CordenPharma
6.19 SRS Pharmaceuticals
6.20 Ankur Drugs and Pharma
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
